)
Investor Relations14 Oct 2025
Boost Your Earnings Season Strategy With Real‑Time Alerts
Quartr Pro provides real time alerts, trend analysis and live coverage, giving analysts and investors instant insights to act faster in earnings.
Catheter Precision (VTAK) investor relations material
Catheter Precision Q2 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q2 2025 earnings summary11 Aug, 2025
Executive summary
Revenue for Q2 2025 increased 128% year-over-year to $212K, with six-month revenue up 103% to $355K, driven by LockeT and VIVO sales; LockeT sales offset a decline in VIVO sales in the EU.
Net loss attributable to the company was $5.1M for Q2 2025 and $9.2M for the six months, compared to $4.2M and $6.9M in the prior year periods, reflecting higher operating and R&D expenses.
CE Mark for LockeT received, enabling European sales to begin in Q3 2025.
Two asset acquisitions completed: Perikard LLC (pericardial access technology) and Cardionomic's CPNS System (late-stage heart failure treatment), both expensed as in-process R&D.
Management notes substantial doubt about the company's ability to continue as a going concern within 12 months due to recurring losses and limited liquidity.
Financial highlights
Q2 2025 revenue: $212K (Q2 2024: $93K); six-month revenue: $355K (2024: $175K).
Q2 2025 net loss: $5.1M (Q2 2024: $4.2M); six-month net loss: $9.2M (2024: $6.9M).
Gross profit for Q2 2025: $198K; gross margin improved due to volume-based discounts on LockeT.
Cash and cash equivalents at June 30, 2025: $838K; accumulated deficit: $301.5M.
Total assets as of June 30, 2025, were $25.6M; shareholders' equity was $6.5M.
Outlook and guidance
Operating losses and negative cash flows expected to continue until sales and gross profit increase sufficiently to cover expenses.
Additional financing will be required before the end of the current quarter to fund operations and repay short-term notes due January 2026.
LockeT sales expected to start in Europe in Q3 2025 following CE Mark approval.
Management is evaluating further ATM offerings and other financing options; failure to secure funding may require operational reductions or suspension.
Management anticipates increased product awareness and demand in both US and international markets.
Liquidity plan beyond Q4 2025?
Remediation plan for internal control weaknesses?
Timeline for Kardionav/Cardionomix product launch?
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Next Catheter Precision earnings date
Q3 202513 Nov, 2025
Next Catheter Precision earnings date
Q3 202513 Nov, 2025
The essential earnings season companion
The #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
Related articles
)
Edge3 Oct 2025
Epiroc: A Culture of Moving Mountains
From automation to electrification, Swedish industrial giant Epiroc is leading a transformation in how the world mines.
)
Company Research22 Sep 2025
Moody's: Shaping Global Credit
Explore Moody's evolution from publishing manuals to becoming a giant in credit ratings, guiding issuers, investors, and regulators worldwide.
Frequently asked questions
Ra Medical Systems, Inc., a medical device company, develops, manufactures, and markets excimer lasers for use in the treatment of vascular and dermatological diseases. The company offers Dabra and Pharos excimer laser products for the treatment of psoriasis and other skin conditions. It serves dermatologists, cardiologists, patients, health insurers with expert medical facilities. Ra Medical Systems markets its products through direct sales forces in the United States and Israel; and through distributors worldwide. The company was founded in 2002 and is headquartered in San Diego, California.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage